July 30, 2024 07:29 AM EDTUpdated 10:17 AM

BioNTech, Regeneron claim Phase 2 win for cancer vaccine, PD-1 combo

Amber Tong

One of BioNTech’s first mRNA cancer vaccine candidates has cleared a key mid-stage trial, setting it up for a potential showdown with a closely-watched and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

BioNTech, Regeneron claim Phase 2 win for cancer vaccine, PD-1 combo

Amber Tong

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Summit's Phase 3 data back up biotech's boasts of beating Keytruda in lung cancer

Exclusive: Influential Democrat will oppose Biosecure Act ahead of House vote

BridgeBio sticks to script for ATTR-CM as Alnylam cleans up ‘typo’ snafu

Astellas CEO talks future beyond Xtandi as Japanese drugmaker puts roots in Boston

Roche's Spark loses CEO to RNA upstart; Ex-Elevation Oncology chief takes over at Affimed

How to secure full enrollment and a 30x ROI: A conversation with the CEO of the boutique enrollment agency doing just ...

BioN­Tech, Re­gen­eron claim Phase 2 win for can­cer vac­cine, PD-1 com­bo

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

BioNTech, Regeneron claim Phase 2 win for cancer vaccine, PD-1 combo